With the third week of June coming to a close, let’s review the hot events of the pharmaceutical industry this week. The news involved 5 sections: approval, R&D, policies, transactions and listing that happened during June 15-19.
Loss Reduced, profit before tax excluding listing expenses amounted to RMB9.1 Million; continuous focus on research and development; lying strong foundation for future growth
European Medicines Agency (EMA) has accepted for review Mylan's Marketing Authorization Applications for proposed biosimilar trastuzumab and proposed biosimilar pegfilgrastim